wire - news in brief

« BACK

Medicine/Pharmacology



Results 1 - 50 of 1495.
1 2 3 4 5 ... 30 Next »


Medicine / Pharmacology - Life Sciences - 20.08.2018
China National Drug Administration grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung cancer
Unsere Webseite verwendet Cookies, um Ihnen einen optimalen Service zu bieten. Durch die Nutzung dieser Webseite erklären Sie sich damit einverstanden.

Business / Economics - Medicine / Pharmacology - 14.08.2018

Medicine / Pharmacology - 10.08.2018

Medicine / Pharmacology - Life Sciences - 03.08.2018
PRIME designation granted by European Medicines Agency for RG6042 for treatment of Huntington’s disease
Unsere Webseite verwendet Cookies, um Ihnen einen optimalen Service zu bieten. Durch die Nutzung dieser Webseite erklären Sie sich damit einverstanden.

Medicine / Pharmacology - 31.07.2018
Roche Purchases Shares in Tender Offer for FMI
Unsere Webseite verwendet Cookies, um Ihnen einen optimalen Service zu bieten. Durch die Nutzung dieser Webseite erklären Sie sich damit einverstanden.

Medicine / Pharmacology - Careers / Employment - 30.07.2018
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention
Novartis marks a new era for migraine patients with the EU approval of Aimovig , a first-of-its-kind treatment specifically designed for migraine prevention Patients on Aimovig (erenumab) in clinical

Medicine / Pharmacology - 27.07.2018
Knowledge brokers connect research, policy and practice
Knowledge brokers connect research, policy and practice
Knowledge brokering is a technical term used to describe activities to facilitate mutual learning between researchers, practitioners and policy makers.

Medicine / Pharmacology - Administration - 27.07.2018
Novartis combination Tafinlar + Mekinist receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma
Phase III trial showed a 53% reduction in risk of recurrence or death with the combination of a BRAF and MEK inhibitor as adjuvant therapy versus placebo   Relapse-free survival benefit with Tafinlar

Medicine / Pharmacology - 25.07.2018
Cross-Cultural Exchange on Health System Performance
Cross-Cultural Exchange on Health System Performance
A workshop was held on 16 to 20 July in Basel, Switzerland, bringing together over 60 Swiss TPH employees including 37 from 14 countries in West and Central Africa and the Middle East.

Medicine / Pharmacology - Life Sciences - 23.07.2018
Novartis renews drug donation of Egaten (triclabendazole) until 2022, reaffirming its commitment to the fight against liver fluke
Novartis extends agreement with the WHO for the donation of Egaten for the treatment of liver fluke, a neglected tropical disease, also known as fascioliasis, that infects more than 2.4 millio

Medicine / Pharmacology - Life Sciences - 20.07.2018
Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer’s Association International Conference
Unsere Webseite verwendet Cookies, um Ihnen einen optimalen Service zu bieten. Durch die Nutzung dieser Webseite erklären Sie sich damit einverstanden.

Medicine / Pharmacology - Life Sciences - 19.07.2018
Roche’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Unsere Webseite verwendet Cookies, um Ihnen einen optimalen Service zu bieten. Durch die Nutzung dieser Webseite erklären Sie sich damit einverstanden.

Medicine / Pharmacology - Life Sciences - 18.07.2018
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women
Novartis Kisqali now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women Kisqal

Business / Economics - Medicine / Pharmacology - 18.07.2018
Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company
Net sales grew 5% (cc , +7% USD) mainly driven by: Cosentyx grew to USD 701 million, (+40% cc) with strong growth in all indications in the US and EU Entresto sales more than doubled to USD 239 millio

Medicine / Pharmacology - Business / Economics - 02.07.2018
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash
Roche commences tender offer for all shares of Foundation Medicine, Inc. for US$ 137.00 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Foundation Medicine, Inc.

Medicine / Pharmacology - 29.06.2018

Medicine / Pharmacology - Life Sciences - 29.06.2018
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe
Novartis receives positive CHMP opinion for Kymriah for treating two aggressive blood cancers, marking important medical advance for patients in Europe First CHMP opinion for a CAR-T cell therapy in

Medicine / Pharmacology - 28.06.2018
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine
Novartis presents new data demonstrating long-term efficacy, safety and tolerability of Aimovig (erenumab) in patients with chronic and episodic migraine Results from a one-year study of efficacy and

Medicine / Pharmacology - Careers / Employment - 27.06.2018
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month
Novartis International AG: Global study by Novartis and European Migraine and Headache Alliance reveals 60% of employed people with severe migraine miss, on average, a week of work per month Study re

Medicine / Pharmacology - Innovation / Technology - 27.06.2018

Medicine / Pharmacology - 26.06.2018
Novartis Clear about Psoriasis survey data highlights challenges psoriasis patients face to achieve goal of clear skin
Survey data published in JEADV show that patients experienced four different treatments and three medical professionals on average before finding an efficacious therapy New publication also highlight

Medicine / Pharmacology - Life Sciences - 21.06.2018
Claudia Daubenberger Appointed Professor at the University of Basel
Claudia Daubenberger Appointed Professor at the University of Basel
The University of Basel appointed Claudia Daubenberger, Head of Clinical Immunology at Swiss TPH, as professor of Infection Biology and Immunology within the Faculty of Science.

Medicine / Pharmacology - Life Sciences - 21.06.2018

Business / Economics - Medicine / Pharmacology - 21.06.2018
Nurseries and crèches: what impact do they have on the development of children under three? - News
Nurseries and crèches: what impact do they have on the development of children under three? Insights from research at HEC Lausanne-UNIL An ever-increasing number of mothers with young children are returning to work.

Medicine / Pharmacology - Innovation / Technology - 18.06.2018
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery
Novartis International AG: Alcon AcrySof IQ PanOptix trifocal intraocular lens shows superior visual performance in head-to-head trial post-cataract surgery Better visual outcomes for patients with t

Medicine / Pharmacology - Life Sciences - 16.06.2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Overall response rate was 52% and median duration of response was not reached at a median follow-up of 14 months, signifying responses were durable   Patients had a 65% chance of being relapse-free o

Medicine / Pharmacology - 15.06.2018

Medicine / Pharmacology - Life Sciences - 15.06.2018
Study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer
Novartis study of real-world data concludes Jakavi is associated with a reduction in risk of death and dangerous blood clots for patients with rare blood cancer Comparison of Jakavi (ruxolitinib) vs.

Medicine / Pharmacology - Social Sciences - 15.06.2018
Novartis survey uncovers real-world impact of immune thrombocytopenia or ITP, a rare blood disease, on patients’ quality of life
Findings from more than 1,300 patients across 13 countries showed ITP had especially high impact for many patients on emotional well-being (36%) and ability to work (28%) About two-thirds of patients

Medicine / Pharmacology - Life Sciences - 14.06.2018
Enigma of fatty acid metabolism solved: Enzyme shape controls its activity
Enigma of fatty acid metabolism solved: Enzyme shape controls its activity
Fats are essential for our body. The core components of all fats are fatty acids. Their production is initiated by the enzyme ACC.

Medicine / Pharmacology - Social Sciences - 07.06.2018
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs
Novartis announces JCO publication of Lutathera NETTER-1 data showing significantly longer time to deterioration of key quality of life measures in patients with progressive midgut NETs Patients repor

Medicine / Pharmacology - Innovation / Technology - 04.06.2018

Medicine / Pharmacology - Life Sciences - 02.06.2018
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell lung cancer
Phase III IMpower131 study showed Tecentriq(atezolizumab) plus chemotherapy (carboplatin and Abraxane) reduced the risk of disease worsening or death for people with advanced squamous non-small cell

Medicine / Pharmacology - Chemistry - 02.06.2018
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy
New Novartis data presented at ASCO find nearly half of CML patients treated with Tasigna remain in remission almost three years after stopping therapy ENESTop and ENESTfreedom data evaluate Treatmen

Medicine / Pharmacology - Business / Economics - 01.06.2018
Sandoz receives positive CHMP opinion for proposed biosimilar adalimumab
Sandoz is seeking approval of proposed biosimilar adalimumab for use in all reference medicine indications including those in rheumatology, gastroenterology and dermatology Positive CHMP opinion base

Administration - Medicine / Pharmacology - 30.05.2018

Innovation / Technology - Medicine / Pharmacology - 30.05.2018
From science to start-ups
The new Bridge programme helps to turn scientific research into actual products and services. A year and a half into its launch, the results are already in. "Without the financial support provided by Bridge, my discovery might have been relegated to the cemetery of good ideas that never materialized," says Olga Dubey, a biologist and a newly minted entrepreneur.

Medicine / Pharmacology - 30.05.2018
FDA expedites review of Novartis drug Promacta for first-line severe aplastic anemia (SAA)
Promacta receives FDA Priority Review for first-line treatment of SAA based on data showing 52% complete response rate and 85% overall response rate when added to standard immunosuppressive therapy (

Medicine / Pharmacology - Life Sciences - 29.05.2018
Phase III IMpower130 study showed Roche’s Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to chemotherapy alone
Phase III IMpower130 study showed Roche's Tecentriq (atezolizumab) plus chemotherapy (carboplatin and Abraxane) helped people with metastatic non-squamous NSCLC live significantly longer compared to

Medicine / Pharmacology - Social Sciences - 28.05.2018
Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto Overall summary score was also significantly higher for Entresto patients than for patients not taking Entresto, as measured by the 12-item Kansas City Cardiomyopathy Questionnaire (KCCQ-12) These improvements were reported early by Entresto patients, with a median follow-up time of 32 days 21&
1 2 3 4 5 ... 30 Next »